Trial News & Events

Mitsubishi Tanabe Pharma announces use of RADICUT for treating ALS patients in Japan

Mitsubishi Tanabe Pharma Corporation issued a press release on June 26 announcing that it had received approval to use RADICUT (Edaravone) in treating patients with ALS in Japan. The announcement comes after a series of clinical trials in Japan were said to demonstrate that patients receiving the drug showed less functional loss than patients receiving a placebo. We look forward to seeing the data supporting approval in Japan. Read press release here.…

DREAM ALS Stratification Prize4Life Challenge

Prize4Life, Sage Bionetwroks and DREAM are proud to anounce the launch of The DREAM ALS Stratification Prize4Life Challenge. The prize, is a computational challenge inviting bioinformatics, statisiticians, computation geeks and math geniuses to work on the PRO-ACT database and identify meaningful subgroups of ALS patients. The challenge offers a $28000 prize and journal partnership with Nature Biotechnology. Read more here.…

Dr. Maragakis on Q Therapeutics’ FDA Clearance for Clinical Trials with Q-Cells in Patients with ALS

Dr. Nicholas Maragakis, professor at Johns Hopkins University School of Medicine and NEALS member, was a key contributor to the pre-clinical development of Q-Cells. Read what he has to say about this research opportunity. Q Therapeutics announced clearance of its investigational new drug application for phase 1/2a clinical trials with Q-Cells in patients with ALS on June 4, 2015. Dr. Nicholas Maragakis, professor at Johns Hopkins University School of Medicine and NEALS member, was a key contributor to the pre-clinical development of Q-Cells. “This has been an amazing opportunity to be a part of the pre-clinical…

Nominate PALS for the 5th Annual ALS CRLI

NEALS is now accepting nominations for the 2015 ALS Clinical Research Learning Institute in Clearwater Beach, Florida from November 6 - 7, 2015. Learn more about the CRLI and the nomination process. The Northeast ALS Consortium (NEALS) is seeking nominations and self-nominations for this year’s ALS Clinical Research Learning Institute. The ALS Clinical Research Learning Institute, sponsored by the ALS Association’s TREAT ALS initiative, is an intensive two day program dedicated to educating attendees on clinical research and therapy development and empowering this group to be advocates for ALS clinical research. Patients and patient-caregiver pairs…